← Leaderboards
Karen L Lindsay
University Of Southern California
$3,850,131
Attributed
$3,850,131
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $544.4K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$3,850,131 · 12
By mechanism
M01$3,153,114 · 10
N01$697,017 · 1
U19$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- J.-H. James Ou$19,172,840
- Tatiana Kisseleva$14,632,761
- Keigo Machida$6,084,542
- Norah A. Terrault$8,729,722
- Neil Kaplowitz$21,379,778
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHepatitis C VirusHepatitis CInterferon AlphaHuman Therapy EvaluationHuman SubjectImmunotherapyChronic Disease /DisorderLiver CirrhosisSourceMicroorganism Disease ChemotherapyResearch PersonnelInstitutionCombination ChemotherapyUnited States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseFundingGrantResourcesMolecular PathologyRibavirinDrug ResistanceHuman TissueCooperative Study
Grant awards (24)
CLINICAL TRIAL: A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE SAFETY OF LONG-TER$135,660
M01 · FY2009 · RR · contact PI
ANCILLARY STUDY TO THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRR$15,072
M01 · FY2009 · RR · contact PI
A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE SAFETY OF LONG-TERM PEGYLATED A-A$311,249
M01 · FY2008 · RR · contact PI
HCV RNA TESTING IN HALT-C SUSTAINED VIROLOGIC RESPONDERS$2,405
M01 · FY2008 · RR · contact PI
A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE SAFETY OF LONG-TERM PEGYLATED A-A$250,999
M01 · FY2007 · RR · contact PI
HCV RNA TESTING IN HALT-C SUSTAINED VIROLOGIC RESPONDERS$1,939
M01 · FY2007 · RR · contact PI
A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE SAFETY OF LONG-TERM PEGYLATED A-A$416,969
M01 · FY2006 · RR · contact PI
A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE SAFETY OF LONG-TERM PEGYLATED A-A$544,371
M01 · FY2005 · RR
A Randomized Controlled Trial to Evaluate the Safety$927,493
M01 · FY2004 · RR
UCDA + MTX versus UCDA + Placebo on PBC$8,559
M01 · FY2004 · RR
NV15496--R025 8310 VERSUS ROFERON A IN PATIENTS W/ CHRONIC HEPATITIS$0
M01 · FY2002 · RR
NV 15495--PEG INTERFERON 2A VS ROBERON A IN PATIENTS W/ CHRONIC HEPATITIS$0
M01 · FY2002 · RR
MECHANISMS OF VIRAL RESISTANCE TO THERAPY IN CHRONIC HCV INFECTION$0
U19 · FY2002 · AI
NV15496--R025 8310 VERSUS ROFERON A IN PATIENTS W/ CHRONIC HEPATITIS$155,764
M01 · FY2001 · RR
NV 15495--PEG INTERFERON 2A VS ROBERON A IN PATIENTS W/ CHRONIC HEPATITIS$155,764
M01 · FY2001 · RR
NV15496--R025 8310 VERSUS ROFERON A IN PATIENTS W/ CHRONIC HEPATITIS$0
M01 · FY2001 · RR
MECHANISMS OF VIRAL RESISTANCE TO THERAPY IN CHRONIC HCV INFECTION$0
U19 · FY2001 · AI
NV 15495--PEG INTERFERON 2A VS ROBERON A IN PATIENTS W/ CHRONIC HEPATITIS$0
M01 · FY2001 · RR
HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERS$697,017
N01 · FY2000 · DK
NV15496--R025 8310 VERSUS ROFERON A IN PATIENTS W/ CHRONIC HEPATITIS$155,764
M01 · FY2000 · RR
NV 15495--PEG INTERFERON 2A VS ROBERON A IN PATIENTS W/ CHRONIC HEPATITIS$35,553
M01 · FY2000 · RR
NV15496--R025 8310 VERSUS ROFERON A IN PATIENTS W/ CHRONIC HEPATITIS$35,553
M01 · FY2000 · RR
MECHANISMS OF VIRAL RESISTANCE TO THERAPY IN CHRONIC HCV INFECTION$0
U19 · FY2000 · AI
NV 15495--PEG INTERFERON 2A VS ROBERON A IN PATIENTS W/ CHRONIC HEPATITIS$0
M01 · FY2000 · RR